



PMPRB Update

February 28, 2024



GLOBAL PUBLIC AFFAIRS
FROM INSIGHT TO IMPACT

Wayne Critchley
Senior Associate
Health and Life Sciences

Major Changes in 2022-24



- Court decisions confirm limited PMPRB mandate:
 - ***Ensure prices of patented medicines not excessive***
- New Regulations in Place
 - Larger basket of lower-priced comparator countries
 - US removed as comparator

- ***New*** Board in place
- Priorities:
 - Organizational stability
 - Consultations: Scoping Paper
 - Outreach to stakeholders
 - Develop new guidelines – winter 2024-2025



Chair: Thomas Digby

PMPRB Highlights – 2022 Annual Report

- Prices up >1%, compared to CPI 6.8%
- Sales of patented medicines up 5.7%
 - Share of GDP dropped to .67% from .83% in 2009
- Patented drugs dropped to 49% all drugs


FIGURE 19. ANNUAL RATE OF CHANGE, PATENTED MEDICINES PRICE INDEX (PMPI) AND CONSUMER PRICE INDEX (CPI), 2003 TO 2022



Note: To account for revised submissions from rights holders, price and quantity indices are recalculated for the five years preceding the current Annual Report year. If the data has been revised, the values reported here may differ from those presented in earlier Annual Reports.

Data source: PMPRB; Statistics Canada

International Price Comparisons



- Canada's prices higher than 7 countries of the 11 comparator countries; lower or tied with 4
- Canada lower than 7 countries using purchasing power comparisons

The Other Side of the Coin

- BC MOH Submission urges active role for PMPRB:
 - BC and pCPA “not able to address the transparent list prices for drugs.”
 - “Public drug plans and the pCPA do not have the authority or the ability to ensure list prices are not excessive.”
- PMPRB Annual Report
 - Includes an alternate price comparison showing Canada 23%, not 1%, above median
 - Scoping Paper: 22% of all drugs above highest; 69% above median
 - Increased spending on EDRDs
 - Top-selling drugs had median annual treatment cost of \$21,345 in 2022 compared to \$803 a decade ago.

PMPRB 2022 Annual Report: High Cost Drugs

KEY PHARMACEUTICAL TRENDS:

HIGHER-COST MEDICINES CONTINUE TO INFLUENCE SALES



High-cost medicines continue to dominate the pharmaceutical landscape

The 20 top-selling medicines in 2022 had a

MEDIAN ANNUAL TREATMENT COST OF \$21,345,
compared to just \$803 in 2013.

SPENDING ON EXPENSIVE DRUGS FOR RARE DISEASES

- increased to 13.4% of total sales from 2.2% in 2013.



Next Steps

- “What We Learned” – February 2024
 - Support for mandate, consultations
- Targeted Consultations – through 2024
 - Key Stakeholders
- Proposals – Fall 2024?
- New Guidelines – 2025?

**CORD continues to be an
important stakeholder for
PMPRB**



‘What We Learned’ Report

Patented Medicine Prices Review Board

Policy Roundtable held December 5th and 6th, 2023, in Ottawa

January 2024